OncBioMune Pharmaceuticals, Inc. Announces Latest Follow-Up Data from the Phase 1a Trial of Proscavax for Prostate Cancer
January 10, 2018 at 07:50 pm IST
Share
OncBioMune Pharmaceuticals, Inc. announced the latest follow-up data from the Company’s Phase 1a trial of ProscaVax for prostate cancer. ProscaVax is OncBioMune's novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). In the trial, 20 hormone-naïve and hormone-independent recurrent prostate cancer patients with increasing PSA were treated with six intradermal injections of ProscaVax. The latest data shows: 14 of 20 (70%) patients have increased PSA Doubling Time (PSADT -the time for serum PSA to double its value and a key metric of disease progression) post-initiation of ProscaVax immunotherapy. This demonstrates a slowing of tumor growth at a minimum of 31 weeks post-initiation of ProscaVax immunotherapy. 15 of 18 patients have increased immunity to PSA at 31 weeks post-initiation of ProscaVax immunotherapy. Of the 20 patients that completed ProscaVax immunotherapy, 4 patients have shown disease progression at 31 weeks and one patient has chosen to withdraw from the study after week 19 without progression and entered another clinical trial. As a subset, of the four patients that demonstrated disease progression at 31 weeks, 3 did not have an increase in their PSADT.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.